Global Sphingosine 1 Phosphate Receptor Modulators Pipeline Insights Market Report 2021 - ResearchAndMarkets.com

The "Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2021 report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 phosphate receptor modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Sphingosine 1 phosphate receptor modulators Emerging Drugs Chapters

This segment of the Sphingosine 1 phosphate receptor modulators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sphingosine 1 phosphate receptor modulators Emerging Drugs

Cenerimod: Idorsia Pharmaceuticals

Cenerimod is a selective sphingosine-1-phosphate 1 (S1P1) receptor modulator, which potentially offers a novel approach for SLE - a disease with limited treatment options. Idorsia is investigating cenerimod, an oral once-daily tablet in patients with SLE. The drug is currently in phase 2 of clinical trials for the treatment of Systemic lupus erythematosus.

Sonepcizumab: Lpath

Lpath is developing sonepcizumab, a first-in-class monoclonal antibody targeting sphingosine-1-phosphate (S1P) for the treatment of cancer as well as various. The drug is in phase 2 of clinical trials for the treatment of Wet age-related macular degeneration

Etrasimod: Arena Pharmaceuticals

Etrasimod is a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena, and designed for optimized pharmacology and engagement of S1P receptor 1, 4 and 5 which may lead to an improved efficacy and safety profile. Etrasimod provides systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn's disease, atopic dermatitis and alopecia areata. The drug is currently in phase 3 of clinical trials for the treatment of Atopic dermatitis; Ulcerative colitis.

Sphingosine 1 phosphate receptor modulators: Therapeutic Assessment

This segment of the report provides insights about the different Sphingosine 1 phosphate receptor modulators drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Sphingosine 1 phosphate receptor modulators

There are approx. 14+ key companies which are developing the Sphingosine 1 phosphate receptor modulators. The companies which have their Sphingosine 1 phosphate receptor modulators drug candidates in the most advanced stage, i.e. phase III include, Arena Pharmaceuticals.

Phases

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Sphingosine 1 phosphate receptor modulators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sphingosine 1 phosphate receptor modulators: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sphingosine 1 phosphate receptor modulators therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sphingosine 1 phosphate receptor modulators drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sphingosine 1 phosphate receptor modulators R&D. The therapies under development are focused on novel approaches for Sphingosine 1 phosphate receptor modulators.

Sphingosine 1 phosphate receptor modulators Report Insights

• Sphingosine 1 phosphate receptor modulators Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sphingosine 1 phosphate receptor modulators Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing Sphingosine 1 phosphate receptor modulators drugs?
• How many Sphingosine 1 phosphate receptor modulators drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Sphingosine 1 phosphate receptor modulators?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sphingosine 1 phosphate receptor modulators therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sphingosine 1 phosphate receptor modulators and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Idorsia Pharmaceuticals
• Lpath
• Bristol-Myers Squibb
• Akaal Pharma
• Oppilan Pharma
• Boston Pharmaceuticals
• Trevena
• Corium International
• Janssen Pharmaceuticals
• Arena Pharmaceuticals
• Curadim Pharma
• Bridge Medicines
• Novartis
• Celgene Corporation
• Mitsubishi Tanabe Pharma Corporation
• LG Chem Life Sciences

Key Products

• Cenerimod
• Sonepcizumab
• BMS 986104
• AKP 11
• OPL 002
• BOS 173717
• TRV 045
• Fingolimod transdermal
• Ponesimod
• Etrasimod
• CP1050
• Siponimod
• Ozanimod
• Amiselimod
• LC51-0255

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/se8lq1

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005678/en/